Affinity Asset Advisors LLC lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 9.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,000 shares of the biopharmaceutical company’s stock after purchasing an additional 22,500 shares during the quarter. Ocular Therapeutix accounts for 1.3% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 17th largest holding. Affinity Asset Advisors LLC owned 0.33% of Ocular Therapeutix worth $3,545,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of OCUL. BlackRock Inc. raised its holdings in shares of Ocular Therapeutix by 6.4% in the 1st quarter. BlackRock Inc. now owns 5,867,062 shares of the biopharmaceutical company’s stock worth $96,278,000 after acquiring an additional 354,798 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Ocular Therapeutix by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,668,965 shares of the biopharmaceutical company’s stock worth $52,025,000 after acquiring an additional 25,902 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Ocular Therapeutix by 6.1% during the second quarter. Geode Capital Management LLC now owns 1,304,799 shares of the biopharmaceutical company’s stock valued at $18,502,000 after purchasing an additional 75,191 shares in the last quarter. FMR LLC boosted its holdings in Ocular Therapeutix by 548.5% during the second quarter. FMR LLC now owns 1,198,937 shares of the biopharmaceutical company’s stock worth $17,001,000 after purchasing an additional 1,014,069 shares during the last quarter. Finally, Great Point Partners LLC grew its position in Ocular Therapeutix by 17.6% in the 1st quarter. Great Point Partners LLC now owns 1,007,012 shares of the biopharmaceutical company’s stock worth $16,525,000 after purchasing an additional 150,850 shares in the last quarter. Hedge funds and other institutional investors own 63.02% of the company’s stock.
A number of analysts recently commented on OCUL shares. JMP Securities reaffirmed a “buy” rating and set a $33.00 price target on shares of Ocular Therapeutix in a research report on Friday, October 8th. Piper Sandler reissued a “buy” rating and set a $28.00 price objective on shares of Ocular Therapeutix in a report on Friday, July 23rd. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Finally, HC Wainwright boosted their price objective on shares of Ocular Therapeutix from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.83.
OCUL stock traded up $0.07 during mid-day trading on Thursday, hitting $11.61. 14,263 shares of the stock were exchanged, compared to its average volume of 958,208. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.05 and a quick ratio of 10.00. The stock has a market capitalization of $889.13 million, a price-to-earnings ratio of -6.04 and a beta of 2.14. The business has a fifty day moving average price of $10.57 and a 200 day moving average price of $13.11. Ocular Therapeutix, Inc. has a 12 month low of $9.11 and a 12 month high of $24.30.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, August 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.09. The business had revenue of $11.72 million during the quarter, compared to analyst estimates of $11.70 million. Ocular Therapeutix had a negative net margin of 318.77% and a negative return on equity of 51.58%. As a group, equities analysts forecast that Ocular Therapeutix, Inc. will post -0.59 EPS for the current fiscal year.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Further Reading: Trading signals using Bollinger bands
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.